Mohamed Yasser, Basyony Mohamed A, El-Desouki Nabila I, Abdo Walied S, El-Magd Mohammed A
Department of Zoology, Faculty of Science, Tanta University, Tanta 31527, Egypt.
Department of Pathology, Faculty of Veterinary Medicine, Kafrelsheikh University, Kafrelsheikh 33516, Egypt.
Biomedicine (Taipei). 2019 Dec;9(4):24. doi: 10.1051/bmdcn/2019090424. Epub 2019 Nov 14.
BACKGROUND/AIM: Herein, we investigated the potential therapeutic effect of Melatonin (Mel) and/or mesenchymal stem cells (MSCs) on rat model of HCC.
Female mature rats were divided into 5 groups (n = 10/group): normal (Nor), HCC group intraperitoneally injected with 200 mg/kg DEN, and 3 treated groups; HCC + Mel (Mel) group given Mel intraperitoneally 20 mg/kg, twice a week, HCC + MSCs (MSCs) group intravenously injected by 1 × 10 cells, and HCC + MSCs (Mel +MSCs) group.
Rats in HCC group showed most deteriorated effect in form of increased mortality and relative liver weight, elevated serum levels of ALT, AST, ALP, AFP and GGT in addition to increased pre-neoplastic nodules in liver tissues. Liver tissues of HCC group also exhibited lower level of apoptosis as indicated by decreased DNA fragmentation and expression of p53 caspase 9 and caspase 3 genes and increased PCNA immunoreactivity. Moreover, in this group the expression of IL6 and TGFβ1 genes was significantly upregulated. All these deleterious effects induced by DEN were reversed after administration of Mel and/ or MSCs with best improvement for the combined group (MSCs + Mel).
These findings reveal a better therapeutic effect for MSCs when given with Mel and we attribute this beneficial effect, at least in part, to triggering apoptosis and targeting inflammation in HCC. Therefore, combined treatment with Mel and MSCs is recommended to enhance the therapeutic potential against HCC.
背景/目的:在此,我们研究了褪黑素(Mel)和/或间充质干细胞(MSCs)对肝癌大鼠模型的潜在治疗作用。
将成年雌性大鼠分为5组(每组n = 10):正常组(Nor)、腹腔注射200 mg/kg二乙基亚硝胺(DEN)的肝癌组以及3个治疗组;肝癌+Mel(Mel)组,每周两次腹腔注射20 mg/kg Mel;肝癌+MSCs(MSCs)组,静脉注射1×10个细胞;肝癌+MSCs(Mel + MSCs)组。
肝癌组大鼠表现出最严重的恶化效应,包括死亡率增加、相对肝脏重量增加、血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、碱性磷酸酶(ALP)、甲胎蛋白(AFP)和γ-谷氨酰转肽酶(GGT)水平升高,此外肝组织中的癌前结节增多。肝癌组肝组织的凋亡水平也较低,表现为DNA片段化减少、p53、半胱天冬酶9和半胱天冬酶3基因表达降低以及增殖细胞核抗原(PCNA)免疫反应性增加。此外,该组白细胞介素6(IL6)和转化生长因子β1(TGFβ1)基因的表达显著上调。给予Mel和/或MSCs后,DEN诱导的所有这些有害效应均得到逆转,联合组(MSCs + Mel)改善效果最佳。
这些发现表明,MSCs与Mel联合使用时具有更好的治疗效果,我们将这种有益效果至少部分归因于在肝癌中引发凋亡和靶向炎症。因此,建议联合使用Mel和MSCs以增强对肝癌的治疗潜力。